Literature DB >> 6282927

The effect of short-term and chronic immunosuppression on Theiler's virus demyelination.

R P Roos, S Firestone, R Wollmann, D Variakojis, B G Arnason.   

Abstract

Theiler's virus (TV)-infected mice were treated with antithymocyte serum (ATS), cyclophosphamide or pepstatin (a protease inhibitor) to determine the effect on demyelination. When ATS and cyclophosphamide were begun at the time of infection there was significantly less demyelination at 2.5-3.5 weeks than in pepstatin or non-treated infected controls. When immunosuppression was continued for 5 weeks, or when it was not started until 5 weeks post-infection, no significant decrease in demyelination was seen compared to controls. The findings indicate that timing of immunosuppression is critical in determining the extent of TV demyelination. Such demyelination may occur by different mechanisms that are active at different times. The "bystander effect' may be important in early demyelination, but late demyelination may be due to other causes, such as oligodendrocyte lytic infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282927     DOI: 10.1016/0165-5728(82)90057-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  36 in total

1.  The interaction of two groups of murine genes determines the persistence of Theiler's virus in the central nervous system.

Authors:  J F Bureau; X Montagutelli; S Lefebvre; J L Guénet; M Pla; M Brahic
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Transgenic expression of viral capsid proteins predisposes to axonal injury in a murine model of multiple sclerosis.

Authors:  Aleksandar Denic; Laurie Zoecklein; Jason Kerkvliet; Louisa Papke; Ramakrishna Edukulla; Arthur Warrington; Allan Bieber; Larry R Pease; Chella S David; Moses Rodriguez
Journal:  Brain Pathol       Date:  2011-02-11       Impact factor: 6.508

3.  The immune system preferentially clears Theiler's virus from the gray matter of the central nervous system.

Authors:  M K Njenga; K Asakura; S F Hunter; P Wettstein; L R Pease; M Rodriguez
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Receptors for Theiler's murine encephalomyelitis virus: characterization by using rabbit antiviral antiserum.

Authors:  N Rubio; A Cuesta
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  An in vitro experimental model of neuroinflammation: the induction of interleukin-6 in murine astrocytes infected with Theiler's murine encephalomyelitis virus, and its inhibition by oestrogenic receptor modulators.

Authors:  Nazario Rubio; Marie Cerciat; Mikko Unkila; Luis M Garcia-Segura; Maria-Angeles Arevalo
Journal:  Immunology       Date:  2011-05-13       Impact factor: 7.397

Review 6.  Effect of the innate immune response on development of Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  Julie K Olson
Journal:  J Neurovirol       Date:  2014-07-01       Impact factor: 2.643

7.  Differential virus replication, cytokine production, and antigen-presenting function by microglia from susceptible and resistant mice infected with Theiler's virus.

Authors:  Young-Hee Jin; Mani Mohindru; Min H Kang; Alyson C Fuller; Bongsu Kang; Daniel Gallo; Byung S Kim
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Identification of a major T-cell epitope within VP3 amino acid residues 24 to 37 of Theiler's virus in demyelination-susceptible SJL/J mice.

Authors:  R L Yauch; K Kerekes; K Saujani; B S Kim
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice.

Authors:  M K Njenga; K D Pavelko; J Baisch; X Lin; C David; J Leibowitz; M Rodriguez
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  Localization of a neutralization site of Theiler's murine encephalomyelitis viruses.

Authors:  S Nitayaphan; M M Toth; R P Roos
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.